Leerink Partnrs Analysts Raise Earnings Estimates for IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Research analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for shares of IDEAYA Biosciences in a research note issued to investors on Monday, September 11th. Leerink Partnrs analyst C. Liu now expects that the company will post earnings per share of ($3.08) for the year, up from their prior forecast of ($3.13). Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for IDEAYA Biosciences’ FY2026 earnings at ($3.24) EPS and FY2027 earnings at ($2.49) EPS.

Other equities research analysts have also recently issued reports about the company. Wedbush lifted their target price on IDEAYA Biosciences from $40.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday. The Goldman Sachs Group lifted their target price on IDEAYA Biosciences from $31.00 to $37.00 and gave the company a “buy” rating in a research note on Tuesday. SVB Leerink assumed coverage on IDEAYA Biosciences in a research note on Tuesday, August 8th. They issued an “outperform” rating and a $33.00 target price for the company. SVB Securities assumed coverage on IDEAYA Biosciences in a research note on Tuesday, August 8th. They issued an “outperform” rating and a $33.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their target price on IDEAYA Biosciences from $28.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday, August 17th. Fourteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $32.08.

IDEAYA Biosciences Price Performance

IDYA stock opened at $29.49 on Thursday. The business has a fifty day moving average price of $24.95 and a 200 day moving average price of $21.26. IDEAYA Biosciences has a fifty-two week low of $10.60 and a fifty-two week high of $30.25. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -20.34 and a beta of 0.75.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. IDEAYA Biosciences had a negative return on equity of 19.09% and a negative net margin of 164.25%. The firm had revenue of $3.50 million during the quarter, compared to analysts’ expectations of $4.89 million. IDEAYA Biosciences’s quarterly revenue was down 55.7% compared to the same quarter last year.

Institutional Investors Weigh In On IDEAYA Biosciences

Several large investors have recently modified their holdings of IDYA. Point72 Asset Management L.P. acquired a new position in shares of IDEAYA Biosciences during the fourth quarter worth about $49,000. Metropolitan Life Insurance Co. NY boosted its position in shares of IDEAYA Biosciences by 39.3% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,743 shares of the company’s stock worth $50,000 after buying an additional 774 shares during the period. Metropolitan Life Insurance Co NY boosted its position in shares of IDEAYA Biosciences by 39.3% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 2,743 shares of the company’s stock worth $50,000 after buying an additional 774 shares during the period. Tucker Asset Management LLC boosted its position in shares of IDEAYA Biosciences by 1,265.5% during the second quarter. Tucker Asset Management LLC now owns 2,813 shares of the company’s stock worth $66,000 after buying an additional 2,607 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of IDEAYA Biosciences by 66.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,847 shares of the company’s stock worth $39,000 after buying an additional 1,136 shares during the period. 98.29% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other IDEAYA Biosciences news, insider Jason Throne sold 5,000 shares of the stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $25.09, for a total value of $125,450.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other IDEAYA Biosciences news, CFO Paul A. Stone sold 3,822 shares of the stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $26.38, for a total value of $100,824.36. Following the completion of the sale, the chief financial officer now directly owns 15,281 shares in the company, valued at $403,112.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jason Throne sold 5,000 shares of the stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $25.09, for a total value of $125,450.00. The disclosure for this sale can be found here. Insiders sold 31,822 shares of company stock worth $827,735 over the last ninety days. 5.10% of the stock is currently owned by corporate insiders.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.